June 2019 Digital Edition

Pipeline watch: we look closely at drugs in phase 2, phase 3 or recently approved for basal cell carcinoma and melanoma. Plus, treating patients with autism, and the physician's impact on regulations and pay.

Subscribe to Dermatology Times!   Print & Digital / eNewsletter